98642-44-5

Basic information

• Product Name: tert-butyl 3-hydroxypropylmethylcarbamate
• Synonyms: tert-butyl 3-hydroxypropylmethylcarbamate;(3-N-BOC-METHYLAMINO)-1-PROPANOL;N-Methyl-N-boc-aminopropan-3-ol;(3-Hydroxy-propyl)-Methyl-carbaMic acid tert-butyl ester;N-(3-Hydroxypropyl)-N-Methyl-;N-Boc-3-(MethylaMino)-1-propanol;tert-Butyl (3-hydroxypropyl)
• CAS NO: 98642-44-5
• Molecular Formula: C₉H₁₉NO₃
• Molecular Weight: 189.25
• Product Categories: Aliphatics;Amines;Miscellaneous Reagents
• Mol File: 98642-44-5.mol

Chemical Properties

• Melting Point: NA
• Boiling Point: 120 °C(Press: 0.08 Torr)
• Appearance: /
• Density: 1.020±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Chloroform, Dichloromethane, DMSO, Ethyl Acetate
• PKA: 14.99±0.10(Predicted)
• CAS DataBase Reference: tert-butyl 3-hydroxypropylmethylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 3-hydroxypropylmethylcarbamate(98642-44-5)
• EPA Substance Registry System: tert-butyl 3-hydroxypropylmethylcarbamate(98642-44-5)

Safety Data

• Hazardous Substances Data: 98642-44-5(Hazardous Substances Data)

Usage

Chemical Properties

Light Yellow Oil

Uses

N-Methyl-N-boc-aminopropan-3-ol (cas# 98642-44-5) is a compound useful in organic synthesis.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 156-87-6 propan-1-ol-3-amine 
• 42055-15-2 N-methyl-3-hydroxypropylamine 
• 114326-12-4 [3-(tert-butyldimethylsilanyloxy)propyl]carbamic acid tert-butyl ester 
• 58885-58-8 N-tert-butoxycarbonyl-3-aminopropanol 
• 42116-55-2 methyl 3-tert-butoxycarbonylaminopropionate 
• 119740-95-3 methyl 3-(N-tert-butoxycarbonyl-N-methyl)-aminopropionate 
• 169268-90-0 3-N-tert-butoxycarbonylamino-N-methyl-1-propene 
• 114326-13-5 N-methyl-N-(tert-butoxycarbonyl)propanolamine tert-butyldimethylsilyl ether 

Downstream Products

• 1246248-48-5 1-(2-{[6-({4-[{3-[(tert-Butoxycarbonyl)(methyl)amino]propyl}(isopropyl)carbamoyl] phenyl}amino)hexanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate 
• 1246247-20-0 1-(2-{[6-({4-[{3-[(tert-butoxycarbonyl)(methyl)amino]propyl}(cyclopropyl)carbamoyl]phenyl}amino)hexanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate 
• 1246248-51-0 1-(2-{[6-({4-[{3-[(tert-butoxycarbonyl)(methyl)amino]propyl}(methoxy)carbamoyl]phenyl}amino)hexanoyl](methyl)amino}ethyl)piperidin-4-yl biphenyl-2-ylcarbamate 
• 1181285-69-7 tert-Butyl 3-(4-(dimethylamino)-4-phenylpiperidin-1-yl)propyl(methyl)-carbamate 
• 1613513-31-7 3,5-dichlorobenzyl 4-(3-((tert-butoxycarbonyl)(methyl)amino)propyl)piperazine-1-carboxylate 
• 114325-83-6 Methyl-[3-(2-oxo-2-phenyl-ethylsulfanyl)-propyl]-carbamic acid tert-butyl ester 
• 868990-44-7 3-[benzyl-(1-phenyl-ethyl)-amino]-5-(tert-butoxycarbonyl-methyl-amino)-pentanoic acid tert-butyl ester 
• 868990-46-9 3-benzyloxycarbonylamino-5-(tert-butoxycarbonyl-methyl-amino)-pentanoic acid tert-butyl ester 
• 905991-57-3 methyl (4-{3-[(tert-butoxycarbonyl)(methyl)amino]propoxy}-3-chlorophenyl)acetate 
• 156-87-6 propan-1-ol-3-amine 
• 42055-15-2 N-methyl-3-hydroxypropylamine 
• 114326-14-6 N-(tert-butoxycarbonyl)-N-methyl-3-chloropropylamine 
• 123183-72-2 N-(tert-butyl)oxycarbonyl-N,N’-trimethyl-1,3-diaminopropane 

Relevant articles and documents

HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

Benzil compound as well as preparation method and application thereof

The invention provides a benzil compound as well as a preparation method and application thereof, the structure of the benzil compound is shown as a formula I, wherein R1 is -(CH2) n-N (CX1Y1Z1) (CX2Y2Z2), n is an integer from 1 to 6, and X1, X2, Y1, Y2, Z1 and Z2 are independently selected from hydrogen or deuterium. The benzil compound provided by the invention is applied to detection of guanidine compounds, can remarkably improve the sensitivity, accuracy and stability of detection, can be used for identifying potential guanidine compounds in a to-be-detected sample, and is low in cost.

Multiplexed Analysis of Endogenous Guanidino Compounds via Isotope-Coded Doubly Charged Labeling: Application to Lung Cancer Tissues as a Case

Endogenous guanidino compounds (GCs), nitrogen-containing metabolites, have very important physiological activities and participate in biochemical processes. Therefore, accurately characterizing the distribution of endogenous GCs and monitoring their concentration variations are of great significance. In this work, a new derivatization reagent, 4,4′-bis[3-(dimethylamino)propyl]benzyl (BDMAPB), with isotope-coded reagents was designed and synthesized for doubly charged labeling of GCs. BDMAPB-derivatized GCs not only promote the MS signal but also form multicharged quasimolecular ions and abundant fragment ions. With this reagent, an isotope-coded doubly charged labeling (ICDCL) strategy was developed for endogenous GCs with high-resolution liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF MS). The core of this methodology is a 4-fold multiplexed set of [d0]-/[d4]-/[d8]-/[d12]-BDMAPB that yields isotope-coded derivatized GCs. Following a methodological assessment, good linear responses in the range of 25 nM to 1 μM with correlation coefficients over 0.99 were achieved. The limit of detection and the limit of quantitation were below 5 and 25 nM, respectively. The intra- and interday precisions were less than 18%, and the accuracy was in the range of 77.3–122.0%. The percentage recovery in tissues was in the range of 85.1–113.7%. The results indicate that the developed method facilitates long-term testing and ensures accuracy and reliability. Finally, the method was applied for the simultaneous analysis of endogenous GCs in four types of lung tissues (solid adenocarcinoma, solid squamous-cell carcinoma, ground-glass carcinoma, and paracancerous tissues) for absolute quantification, nontargeted screening, and metabolic difference analysis. It is strongly believed that ICDCL combined with isotope-coded BDMAPB will benefit the analysis and study of endogenous GCs.

RAPAFUCIN DERIVATIVE COMPOUNDS AND METHODS OF USE THEREOF

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have grea

NITROXOLINE PRODRUG AND USE THEREOF

Provided are a nitroxoline prodrug and a use thereof. Specifically, provided are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method therefor, a composition containing the compound, and a use thereof in the preparation of anti-infective and antitumor drugs, and definitions of groups in formula (I) are as stated in the specification. The compound represented by formula (I) has better pharmacokinetic parameters such as solubility, blood medicine concentration, or half-life period than nitroxoline. The compound represented by formula (I) can reduce the frequency of drug administration, and has potential for application in other fields other than the field of urinary tracts.

PRODRUG OF NITROXOLINE AND USE THEREOF

The present invention relates to the prodrug of nitroxoline and use thereof. Specifically, the present invention relates to a compound of formula (I) or the pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition comprising the same, as well as a use thereof in anti-infective and anti-tumor drugs. The compound of formula (I) has better pharmacokinetic parameters such as water solubility, blood concentration or half-life relative to nitroxoline. The compound of formula (I) can reduce the number of administrations, and has the possibility of being applied in other fields than the urinary tract field. The definition of each group in formula (I) is as defined in the description.

Preparation method 3 - (tert-butyloxycarbonylamino) propionic acid

The preparation method of 3 - (t-butoxycarbonylamino) propionic acid comprises the following steps: Step S1, reacting methylaminopropanol with Boc anhydride to generate 3 - (t-butoxycarbonylamino) propanol. Step S2: The 3 - (t-butoxycarbonyl) propanol is subjected to an oxidation reaction under the action of a catalyst to generate the 3 - (t-butoxycarbonylamino) propionic acid. To the preparation method disclosed by the embodiment of the invention, the steps are simple, and the reaction is easy to process. Can be suitable for a pot method, can effectively reduce the waste water that is difficult to handle. The method is more suitable for industrial production.

HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Highly chemoselective, sterically sensitive NHC-catalysed amine acylation with pyridil

A new strategy for the protection of amines has been developed involving reaction with pyridil under the influence of N-heterocyclic carbene catalysis. The methodology is capable of distinguishing between two amines characterised by small differences in steric bulk and the resulting pyridoyl amides can be cleaved without requiring either strongly acidic or basic hydrolysis.

COMPOUNDS AND METHODS FOR TRANS-MEMBRANE DELIVERY OF MOLECULES

The Invention provides a novel delivery system for delivery of drugs across biological membranes. It provides novel chemical conjugates that comprise said delivery system, methods for synthesis of said compounds, and methods for utilization of said delivery system, among others, for delivery of genetic drugs into tissues and cells, in vitro, ex vivo, and in vivo, for the treatment of various medical disorders.